Findings

What do systematic reviews say?

1,733 questions · 1,794 findings · 326 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 243 · 13.5%GRADE not reported 96 · 5.4%Very low 597 · 33.3%Low 506 · 28.2%Moderate 303 · 16.9%High 49 · 2.7%

Bae: AZT/3TC/NVP vs Short Course AZT/sdNVP

Maternal Resistance · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

It is very uncertain whether lehman: AZT/3TC/NVP changes maternal Resistance compared with short Course AZT/sdNVP (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.24 [0.07, 0.88]
1 study · 27 participants
Very low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

HIV Transmission or Death at 12 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes infant HIV Transmission or Death at 12 months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.64 [0.44, 0.92]
1 study · 765 participants
Very low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Infant Mortality at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (moderate certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.78 [0.43, 1.42]
1 study · 781 participants
Moderate

Bae: AZT/3TC/NVP vs Other Short Course PMTCT Regimen

Stillbirth · ART‐Eligible HIV‐infected Pregnant Women

It is very uncertain whether ekouevi: AZT/3TC/NVP changes stillbirths compared with other Short Course PMTCT Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.16 [0.34, 3.93]
1 study · 326 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course PMTCT Regimen

Low birthweight · ART‐Eligible HIV‐infected Pregnant Women

It is very uncertain whether ekouevi: AZT/3TC/NVP changes infant Low Birth Weight compared with other Short Course PMTCT Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.81 [1.09, 3]
1 study · 309 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course PMTCT Regimen

Mother to Child Transmission at 12 Months · ART‐Eligible HIV‐infected Pregnant Women

It is very uncertain whether ekouevi: AZT/3TC/NVP changes mother to Child Transmission at 12 Months compared with other Short Course PMTCT Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.14 [0.04, 0.47]
1 study · 311 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course Regimen

HIV Transmission or Death at 1 Month · HIV‐infected pregnant women

It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes HIV Transmission or Death at 1 Month compared with other Short Course Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.86 [0.25, 2.97]
1 study · 218 participants
Very low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Infant Mortality at 12 months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 12 months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.63 [0.38, 1.03]
1 study · 751 participants
Low

Bae: AZT/3TC/NVP vs Other Short Course Regimen

HIV Transmission or Death at 12 Months · HIV‐infected pregnant women

It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes HIV Transmission or Death at 12 Months compared with other Short Course Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.86 [0.42, 1.77]
1 study · 189 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course Regimen

Infant Mortality at 1 Month · HIV‐infected pregnant women

It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes infant Mortality at 1 Month compared with other Short Course Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.33 [0.27, 6.47]
1 study · 231 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course Regimen

Maternal Grade 3/4 Severe Adverse Events Requiring Treatment Modification · HIV‐infected pregnant women

It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes maternal Grade 3/4 Severe Adverse Events Requiring Treatment… compared with other Short Course Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 25.33 [1.49, 430.51]
1 study · 250 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course Regimen

Low birthweight · HIV‐infected pregnant women

It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes infant Low Birth Weight compared with other Short Course Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 2.17 [1.23, 3.81]
1 study · 231 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course Regimen

Stillbirth · HIV‐infected pregnant women

It is very uncertain whether tonwe‐Gold continued: AZT/3TC/NVP changes stillbirths compared with other Short Course Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.89 [0.26, 3.08]
1 study · 241 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course Regimen

Maternal Mortality at Delivery · HIV‐infected pregnant women

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 241 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course Regimen

Mother to Child Transmission at 1 Month · HIV‐infected pregnant women

It is very uncertain whether tonwe‐Gold continued: AZT/3TC/NVP changes mother to Child Transmission of HIV at 1 Month compared with other Short Course Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.32 [0.04, 2.83]
1 study · 217 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course Regimen

Mother to Child Transmission at 12 Months · HIV‐infected pregnant women

It is very uncertain whether tonwe‐Gold continued: AZT/3TC/NVP changes mother to Child Transmission of HIV at 12 Months compared with other Short Course Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.4 [0.11, 1.41]
1 study · 188 participants
Very low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Maternal Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes maternal Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.09 [0.77, 1.53]
1 study · 824 participants
Very low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Infant Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.95 [0.77, 1.16]
1 study · 805 participants
Low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Prematurity · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes prematurity compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.23 [0.85, 1.79]
1 study · 805 participants
Very low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Low birthweight · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in low Birth Weight compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.46 [0.94, 2.25]
1 study · 805 participants
Low